Powered for progress
and breakthrough.
Partnered with
Partnered with
Tissue agnostic Antigen Rich Tumors in PD1 Resistant Population
Additional solid tumors
Partnered with
Partnered with
Cold tumors
STAR0602 is Marengo’s first T cell activator generated from Marengo’s STAR platform that provides a ‘dual boost’ to elevate T cells function and response to tumors. STAR0602 acts on a broad range of tumor antigen-specific Vβ6/10 T cells which are prevalent across many common cancer types (approx. 10-12% of TILs in each common cancer). By combining a novel non-clonal mode of TCR activation with a T cell co-stimulator delivered to the same T cells, it promotes the expansion of a new population of clonally diverse, effector memory Vβ 6/10 T cells that turbo-charges the anti-tumor immune response and promotes durable clearance of cancer cells. STAR0602 has undergone extensive preclinical testing, which demonstrates potent anti-tumor activity in both mouse and human ex vivo tumor models attributed to a distinct mechanism of action from existing cancer immunotherapies.
START-001 is a Phase I/II clinical trial evaluating the safety, tolerability, and preliminary clinical activity of STAR0602 as a single agent in biomarker selected patients with advanced antigen-rich solid tumors including PD-1 refractory and rare tumors. This open-label, multi-center trial consists of two parts: Phase I dose escalation and Phase II dose expansion. For more information, please visit clinicaltrials.gov (trial identifier: NCT05592626).
For patients interested in enrolling in this study contact: kliu@marengotx.com
